ImmunoGen, Inc. Initiates Phase II Clinical Trial of HuC242-DM4
CAMBRIDGE, Mass.--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops novel targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, announced today that the Company has initiated a Phase II clinical study …